Skip to main content

Meritxell Genesca Ferrer

I am a senior investigator at the infectious diseases department where I lead projects focused on defining protective immune responses against pathogens in order to develop new therapies. I have mainly worked on cervicovaginal mucosa immunity, a tissue with a high impact on public health as the portal of entry for sexually transmitted infections such as HIV. The knowledge acquired during my scientific career has served to expand my research towards the understanding of immune protection against pathogens in other tissues, such as against SARS-CoV-2 in the lung.

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca

Meritxell Genesca Ferrer

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca

I am a senior investigator at the infectious diseases department where I lead projects focused on defining protective immune responses against pathogens in order to develop new therapies. I have mainly worked on cervicovaginal mucosa immunity, a tissue with a high impact on public health as the portal of entry for sexually transmitted infections such as HIV. The knowledge acquired during my scientific career has served to expand my research towards the understanding of immune protection against pathogens in other tissues, such as against SARS-CoV-2 in the lung.

Dr. Meritxell Genescà is an expert on cervical mucosal immunology and infectious diseases. She obtained the Extraordinary Award from the Autonomous University of Barcelona as a Doctor in Veterinary Medicine (2000). After obtaining her PhD in physiology (2001-2004, IIBB-CSIC), she was contracted by the University of California first as a postdoctoral researcher and then as an Associate Researcher Immunologist. For the next six years, she worked on the top animal model for HIV sexual transmission studies and specialized in mucosal immunology. In 2011, she joined the Institut d’Investigació Germans Trias i Pujol in Badalona, through a Ramón y Cajal contract, before moving to her current institution in 2017. Dr. Genescà is interested on defining the nature of protective immune responses against pathogens that use the cervicovaginal mucosa as their portal of entry, such as HIV. Her group collaborates with several basic and clinical research groups in order to conduct translational comparative medicine in the following areas: 1) HIV reservoir characterization in the cervical tissue and new strategies for its elimination; 2) Sexually Transmitted Infections and increased risk of co-infection; 3) Adjuvants and biomarkers of mucosal immunity; 4) Tissue explant models to study host-pathogen interaction and immunity (including SARS-CoV-2).
She is a member of the international Society for Mucosal Immunology (SMI), the Spanish group for AIDS study (GESIDA) and the Spanish HIV/AIDS Network (RIS). Moreover, she has participated in many dissemination activities, such as career orientation and continuous education for seniors, among others. Her track record includes over 35 articles in major international scientific journals (https://orcid.org/0000-0001-6413-3812) with an h-index of 20, numerous presentations in international meetings and several fellowships and awards. She is also actively involved in teaching and student training.

Projects

Plataformas basadas en la immunologia de las mucosas para el desarrollo de vacunas de nueva generación

IP: Meritxell Genesca Ferrer
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 199287
Reference: CNS2022-135549
Duration: 01/09/2023 - 31/08/2025

Ministerio de Ciencia

Charting SARS-CoV-2 entry factors in human tissues

IP: Meritxell Genesca Ferrer
Collaborators: David Perea Pérez, María José Buzón Gómez, Ana Gallego Cortes
Funding agency: Fundació La Marató de TV3
Funding: 138750
Reference: 2021121
Duration: 23/09/2021 - 22/09/2023

Induction of CD8+ Resident Memory T cell phenotypes to eliminate viral reservoirs

IP: Meritxell Genesca Ferrer
Collaborators: -
Funding agency: GILEAD SCIENCES SLU
Funding: 49997.2
Reference: GLD21-00049
Duration: 01/07/2022 - 30/06/2024

ISIDORe

IP: Meritxell Genesca Ferrer
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 4471.25
Reference: ISIDORE_HE-INFRA-EMERGENCY2021
Duration: 01/02/2022 - 31/01/2025

Related news

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.

The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease

The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.

Related professionals

Lucía Gutiérrez Ruiz

Lucía Gutiérrez Ruiz

Research technician
Clinical Neuroimmunology
Read more
Vanesa Dávalos Yerovi

Vanesa Dávalos Yerovi

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Joan Daniel Vargas Figueroa

Joan Daniel Vargas Figueroa

Research assistant
Stroke research
Read more
Marc Patricio Liebana

Marc Patricio Liebana

Predoctoral researcher
Nephrology and kidney transplantation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.